1
Clinical Trials associated with Adalimumab biosimilar(Mabscale)Randomized Double Blind Phase III Trial Comparative Clinical Safety, Efficacy and Immunogenicity of Adalimumab (Manufactured by Mabscale, LLC) to Humira®.
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.
The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.
100 Clinical Results associated with Adalimumab biosimilar(Mabscale)
100 Translational Medicine associated with Adalimumab biosimilar(Mabscale)
100 Patents (Medical) associated with Adalimumab biosimilar(Mabscale)
100 Deals associated with Adalimumab biosimilar(Mabscale)